ImmunityBio Inc. (IBRX)
NASDAQ: IBRX
· Real-Time Price · USD
2.47
0.01 (0.41%)
At close: Sep 26, 2025, 11:05 AM
0.41% (1D)
| Bid | 2.46 |
| Market Cap | 2.33B |
| Revenue (ttm) | 56.6M |
| Net Income (ttm) | -367.09M |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -5.14 |
| Forward PE | -6.94 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.47 |
| Volume | 1,716,128 |
| Avg. Volume (20D) | 9,068,114 |
| Open | 2.45 |
| Previous Close | 2.46 |
| Day's Range | 2.44 - 2.50 |
| 52-Week Range | 1.83 - 7.48 |
| Beta | -0.07 |
| Ex-Dividend Date | n/a |
About IBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsImmunityBio Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.78%
ImmunityBio shares are trading higher after the co...
Unlock content with
Pro Subscription
1 month ago
-0.88%
IBRX stock has given up its prior gain. ImmunityBio shares were trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
2 weeks ago · seekingalpha.com
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is TickingI maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of f...
1 month ago · businesswire.com
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVIDCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored ...
